利妥昔单抗治疗微小病变肾病和特发性局灶节段性肾小球硬化的快速卫生技术评估  

Rituximab in the Treatment of Minimal Change Nephropathy and Idiopathic Focal Segmental Glomerulosclerosis:A Rapid Health Technology Assessment

作　　者：邓爱清[1] 范小飞 赵诚 周盈莹[1] DENG Aiqing;FAN Xiaofei;ZHAO Cheng;ZHOU Yingying(Department of Pharmacy,Afiliated Hospital of Nantong University,Nantong,Jiangsu 226001,China)

机构地区：[1]南通大学附属医院药学部,江苏南通226001

出　　处：《今日药学》2024年第7期521-526,共6页Pharmacy Today

基　　金：江苏省药学会-恒瑞医院药学基金科研项目(H202136)。

摘　　要：目的 评价利妥昔单抗治疗微小病变肾病(MCD)和特发性局灶节段性肾小球硬化(FSGS)的有效性、安全性和经济性。方法 检索中国知网、PubMed等数据库,并由2名研究者对数据进行处理与分析。结果 最终纳入1篇HTA报告、6篇系统评价/Meta分析和1篇经济学研究。在有效性方面,利妥昔单抗对原发性、激素依赖或频繁复发MCD和FSGS患者具有显著疗效,对肾移植后复发性MCD和FSGS患者的疗效尚不明确。在安全性方面,利妥昔单抗不良事件发生率较低。在经济性方面,利妥昔单抗的年医疗费用与钙调磷酸酶抑制剂(CNI)相当。结论 利妥昔单抗对原发性、激素依赖或频繁复发MCD和FSGS成人患者具有显著疗效,安全性较好,经济性尚需结合更权威的研究进一步评价。OBJECTIVE To evaluate the effectiveness,safety,and economy of rituximab in the treatment of minimal change disease(MCD) and idiopathic focal segmental glomerulosclerosis(FSGS). METHODS CNKI,PubMed and other databases were systematically searched. Two researchers conducted data process and analysis. RESULTS A total of 1 HTA report,6 systematic reviews/Meta-analysis,and 1 economic study were included. In terms of effectiveness,rituximab had significant efficacy in the treatment of primary and steroid-dependent or frequently relapsing MCD and FSGS,and the efficacy in the treatment of recurrent MCD and FSGS after kidney transplantation was unknown. In terms of safety,the incidence of adverse events was low. In terms of economy,the annual medical expenses of rituximab were comparable to those of the calcineurin inhibitor(CNI). CONCLUSION Rituximab has significant efficacy in adult patients with primary and steroid-dependent or frequently relapsing MCD and FSGS,and the level of ADR is low. The economy still needs to be further evaluated in conjunction with more authoritative research.

关 键 词：利妥昔单抗 微小病变肾病 特发性局灶节段性肾小球硬化 快速卫生技术评估 

分 类 号：R969[医药卫生—药理学]